Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...
The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback